CORAL SPRINGS, FL--(Marketwire - August 09, 2010) -
| Highlighted Links |
Nyloxin Chronic Pain Relief |
Nutra Pharma Corporation |
"We are excited to be working with Amarey Nova Medical to introduce Nyloxin throughout the Colombian healthcare market," explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "As one of the leading pharmaceutical distributors in Colombia, Amarey brings the expertise and ability to support the growth of new healthcare products such as Nyloxin throughout Colombia," he added.
Amarey Nova Medical S.A., which offers over 23 years of experience in the Colombian pharmaceutical market, provides 100% sales coverage throughout Colombia. The Company's sales force is located in Bogota, Cali, Medellin, Barranquilla, Bucaramanga, Cucuta, and Pereira. Companies, whose products are represented by Amarey, include Eli Lilly, Pfizer, Stryker, Merck Novo Nordisk, and Roche.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Adrenomyeloneuropathy (AMN), Multiple Sclerosis (MS), and Human Immunodeficiency Virus (HIV). Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin and Nyloxin. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com
SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. Announcing Amarey Nova Medical as the Company's exclusive Nyloxin distributor in Colombia should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
Digg this
Bookmark with del.icio.us
Add to Newsvine
Technorati:
